|
1
|
Gavel A: Chronic myelogenous leukemia; a
case report. Can J Med Technol. 8:52–54. 1946.PubMed/NCBI
|
|
2
|
Kantarjian HM, Smith TL, McCredie KB,
Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E and
Freireich EJ: Chronic myelogenous leukemia: A multivariate analysis
of the associations of patient characteristics and therapy with
survival. Blood. 66:1326–1335. 1985.PubMed/NCBI
|
|
3
|
Frei E III, Tjio JH, Whang J and Carbone
P: Studies of the philadelphia chromosome in patients with chronic
myelogenous leukemia. Ann N Y Acad Sci. 113:1073–1080. 1964.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trotta R, Vignudelli T, Candini O, Intine
RV, Pecorari L, Guerzoni C, Santilli G, Byrom MW, Goldoni S, Ford
LP, et al: BCR/ABL activates mdm2 mRNA translation via the La
antigen. Cancer Cell. 3:145–160. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oliner JD, Kinzler KW, Meltzer PS, George
DL and Vogelstein B: Amplification of a gene encoding a
p53-associated protein in human sarcomas. Nature. 358:80–83. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feinstein E, Cimino G, Gale RP, Alimena G,
Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A and Canaani
E: p53 in chronic myelogenous leukemia in acute phase. Proc Natl
Acad Sci USA. 88:6293–6297. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peterson LF, Mitrikeska E, Giannola D, Lui
Y, Sun H, Bixby D, Malek SN, Donato NJ, Wang S and Talpaz M: p53
stabilization induces apoptosis in chronic myeloid leukemia blast
crisis cells. Leukemia. 25:761–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahdi T, Alcalay D, Cognard C, Tanzer J
and Kitzis A: Rescue of K562 cells from MDM2-modulated
p53-dependent apoptosis by growth factor-induced differentiation.
Biol Cell. 90:615–627. 1998. View Article : Google Scholar
|
|
9
|
Rizzo MG, Zepparoni A, Cristofanelli B,
Scardigli R, Crescenzi M, Blandino G, Giuliacci S, Ferrari S, Soddu
S and Sacchi A: Wt-p53 action in human leukaemia cell lines
corresponding to different stages of differentiation. Br J Cancer.
77:1429–1438. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang EB, Zhang K, Cheng LY and Mack P:
Butein, a specific protein tyrosine kinase inhibitor. Biochem
Biophys Res Commun. 245:435–438. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JC, Lee KY, Kim J, Na CS, Jung NC,
Chung GH and Jang YS: Extract from Rhus verniciflua Stokes is
capable of inhibiting the growth of human lymphoma cells. Food Chem
Toxicol. 42:1383–1388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Selvam C, Jachak SM and Bhutani KK:
Cyclooxygenase inhibitory flavonoids from the stem bark of
Semecarpus anacardium Linn. Phytother Res. 18:582–584. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan SC, Chang YS, Wang JP, Chen SC and
Kuo SC: Three new flavonoids and antiallergic, anti-inflammatory
constituents from the heartwood of Dalbergia odorifera. Planta Med.
64:153–158. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho SG, Woo SM and Ko SG: Butein
suppresses breast cancer growth by reducing a production of
intracellular reactive oxygen species. J Exp Clin Cancer Res.
33(51)2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee JO, Moon JW, Lee SK, Kim SM, Kim N, Ko
SG, Kim HS and Park SH: Rhus verniciflua extract modulates survival
of MCF-7 breast cancer cells through the modulation of
AMPK-pathway. Biol Pharm Bull. 37:794–801. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khan N, Adhami VM, Afaq F and Mukhtar H:
Butein induces apoptosis and inhibits prostate tumor growth in
vitro and in vivo. Antioxid Redox Signal. 16:1195–1204. 2012.
View Article : Google Scholar :
|
|
17
|
Kim N: Butein sensitizes human leukemia
cells to apoptosis induced by tumor necrosis factor-related
apoptosis inducing ligand (TRAIL). Arch Pharm Res. 31:1179–1186.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iwashita K, Kobori M, Yamaki K and
Tsushida T: Flavonoids inhibit cell growth and induce apoptosis in
B16 melanoma 4A5 cells. Biosci Biotechnol Biochem. 64:1813–1820.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lubbert M, Miller CW, Crawford L and
Koeffler HP: p53 in chronic myelogenous leukemia. Study of
mechanisms of differential expression. J Exp Med. 167:873–886.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sen S, Takahashi R, Rani S, Freireich EJ
and Stass SA: Expression of differentially phosphorylated Rb and
mutant p53 proteins in myeloid leukemia cell lines. Leuk Res.
17:639–647. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zell JA, Ramakrishnan R and Rathinavelu A:
Regulation of mdm2 mRNA expression in human breast tumor-derived
GI-101A cells. Life Sci. 71:2331–2339. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harikumar KB, Kunnumakkara AB, Ahn KS,
Anand P, Krishnan S, Guha S and Aggarwal BB: Modification of the
cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by
xanthohumol leads to suppression of NF-kappaB-regulated gene
products and potentiation of apoptosis in leukemia cells. Blood.
113:2003–2013. 2009. View Article : Google Scholar
|
|
23
|
Lu TL, Huang GJ, Wang HJ, Chen JL, Hsu HP
and Lu TJ: Hispolon promotes MDM2 downregulation through
chaperone-mediated autophagy. Biochem Biophys Res Commun.
398:26–31. 2010. View Article : Google Scholar : PubMed/NCBI
|
